Table 2 (abstract P076). Summary of adverse events (AE) upto last follow up visit (LFU) in REPROVE and RECLAIM studies
From: 39th International Symposium on Intensive Care and Emergency Medicine
| Â | INDIAN POPULATION | OVERALL POPULATION | ||
|---|---|---|---|---|
REPROVE study | ||||
 n (%) | CAZ-AVI (n=36) | MER (n=42) | CAZ-AVI (N=529) | MER (N=529) |
 Any AE | 23 (63.9) | 33(78.6) | 302 (74.6) | 299 (74.2) |
 Any AE leading to death | 0 | 0 | 26(6.4) | 23 (5.7) |
 Any serious AE | 0 | 0 | 75(18.5) | 54(13.4) |
 Any AE leading to discontinuation | 0 | 0 | 16(4.0) | 11(2.7) |
 Any AE of severe intensity | 0 | 0 | 66 (16.3) | 51 (12.7) |
RECLAIM study | ||||
 n (%) | CAZ-AVI + MTZ (n=62) | MER (n=63) | CAZ-AVI + MTZ (N=529) | MER (N=529) |
 Any AE | 44 (71.0) | 35(55.6) | 243 (45.9) | 227 (42.9) |
 Any AE leading to death | 1(1.6) | 0 | 8 (1.5) | 5 (0.9) |
 Any serious AE | 1(1.6) | 1(1.6) | 42(7.9) | 40(7.6) |
 Any AE leading to discontinuation | 1(1.6) | 2(3.2) | 14(2.6) | 191.6) |
 Any AE of severe intensity | 1(1.6) | 1(1.6) | 30 (5.7) | 36 (6.8) |